DE69840334D1 - Puffern zur stabilizierung von hcv antigenen - Google Patents

Puffern zur stabilizierung von hcv antigenen

Info

Publication number
DE69840334D1
DE69840334D1 DE69840334T DE69840334T DE69840334D1 DE 69840334 D1 DE69840334 D1 DE 69840334D1 DE 69840334 T DE69840334 T DE 69840334T DE 69840334 T DE69840334 T DE 69840334T DE 69840334 D1 DE69840334 D1 DE 69840334D1
Authority
DE
Germany
Prior art keywords
buffers
stabilizing
antigenes
hcv
antigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69840334T
Other languages
German (de)
English (en)
Inventor
David Y Chien
Phillip Arcangel
Stephen Tirell
Wanda Ziegler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics Inc
Application granted granted Critical
Publication of DE69840334D1 publication Critical patent/DE69840334D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/108331—Preservative, buffer, anticoagulant or diluent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
    • Y10T436/2525—Stabilizing or preserving

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69840334T 1997-09-22 1998-09-22 Puffern zur stabilizierung von hcv antigenen Expired - Lifetime DE69840334D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5970397P 1997-09-22 1997-09-22
PCT/US1998/019694 WO1999015901A1 (en) 1997-09-22 1998-09-22 Buffers for stabilizing antigens

Publications (1)

Publication Number Publication Date
DE69840334D1 true DE69840334D1 (de) 2009-01-22

Family

ID=22024698

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69840334T Expired - Lifetime DE69840334D1 (de) 1997-09-22 1998-09-22 Puffern zur stabilizierung von hcv antigenen

Country Status (9)

Country Link
US (2) US6261764B1 (enExample)
EP (1) EP1021723B1 (enExample)
JP (2) JP4427182B2 (enExample)
AT (1) ATE417275T1 (enExample)
AU (1) AU9498098A (enExample)
CA (1) CA2303165C (enExample)
DE (1) DE69840334D1 (enExample)
ES (1) ES2316171T3 (enExample)
WO (1) WO1999015901A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4428705A1 (de) * 1994-08-12 1996-02-15 Boehringer Mannheim Gmbh Rekombinantes Antigen aus der NS3-Region des Hepatitis C Virus
DE69840334D1 (de) * 1997-09-22 2009-01-22 Novartis Vaccines & Diagnostic Puffern zur stabilizierung von hcv antigenen
US20080064108A1 (en) * 1997-12-10 2008-03-13 Tony Baker Urine Preservation System
US7569342B2 (en) * 1997-12-10 2009-08-04 Sierra Molecular Corp. Removal of molecular assay interferences
ATE293159T1 (de) 1999-12-14 2005-04-15 Thermo Biostar Inc Stabilisierendes verdünnungsmittel für polypeptide und antigene
AU2001276703A1 (en) * 2000-08-01 2002-02-13 International Reagents Corporation Method of pretreating sample
US20030170618A1 (en) * 2001-02-02 2003-09-11 Chien David Y. Buffers for stabilizing antigens
US20020141970A1 (en) * 2001-03-05 2002-10-03 Pettit Dean K. Stable aqueous solutions of granulocyte macrophage colony-stimulating factor
RU2206095C1 (ru) * 2001-10-09 2003-06-10 Пермское научно-производственное объединение "Биомед" ТЕСТ-СИСТЕМА ДЛЯ ОПРЕДЕЛЕНИЯ АНТИТЕЛ К HBs-АНТИГЕНУ И БЛОКАТОР В ТЕСТ-СИСТЕМЕ
JP4744298B2 (ja) 2003-10-28 2011-08-10 株式会社先端生命科学研究所 Ｃ型肝炎ウイルスの検出方法
US20050186642A1 (en) 2004-02-24 2005-08-25 Biocare Medical, Inc. Immunoassay reagents and methods of use thereof
ITMI20040858A1 (it) * 2004-04-29 2004-07-29 Farma Dev S R L Anticorpi monoclonali ibridomi metodo migliorato per determinare la proteina ptx3 e kit per detta determinazione
CA2616189C (en) * 2005-07-22 2019-03-26 Progenics Pharmaceuticals, Inc. Methods for reducing viral load in hiv-1-infected patients
BRPI0520505B1 (pt) * 2005-09-01 2015-03-31 José Luis Nuño Ayalá Fórmula estabilizadora de vacinas com antígenos vivos para uso em sistemas de vacinação em massa
US20080108147A1 (en) * 2006-11-03 2008-05-08 Tie Wei Reduction of non-specific binding in immunoassays
US20090068635A1 (en) * 2007-09-06 2009-03-12 Muerhoff Anthony S Indirectly labelled assay conjugates and methods of preparing and using same
JP5221121B2 (ja) * 2007-12-27 2013-06-26 キヤノン株式会社 絶縁膜の形成方法
US20110065108A1 (en) * 2008-02-01 2011-03-17 Siemens Healthcare Diagnostics Inc. Urine Transport Medium
JP4593665B2 (ja) * 2008-03-27 2010-12-08 三洋化成工業株式会社 ミオグロビン含有水溶液
US9487837B2 (en) 2008-10-06 2016-11-08 Morehouse School Of Medicine Exosome-mediated diagnosis of hepatitis virus infections and diseases
US10545149B2 (en) * 2008-10-06 2020-01-28 Morehouse School Of Medicine Detection of HIV-related proteins in urine
EP2446269A1 (en) * 2009-06-26 2012-05-02 Atlas Antibodies AB Improvement of immunodetectability
JP5827948B2 (ja) * 2009-08-17 2015-12-02 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ウイルスを単離する方法
HUE033492T2 (en) * 2009-10-26 2017-12-28 Genentech Inc Tests for the detection of antibodies specific for therapeutic anti-verb antibodies and their use in anaphylaxis
CN102081018A (zh) * 2009-11-30 2011-06-01 希森美康株式会社 样品的预处理方法及hcv的免疫测定方法
WO2012154983A2 (en) 2011-05-10 2012-11-15 Biocare Medical, Llc Systems and methods for anti-pax8 antibodies
US10316103B1 (en) 2012-03-30 2019-06-11 Biocare Medical, Llc Systems and methods for anti-Uroplakin III antibodies
JP6004744B2 (ja) * 2012-05-28 2016-10-12 栄研化学株式会社 検体希釈浮遊液およびそれを含む容器
EP2900265B1 (en) 2012-09-27 2018-05-30 Biocare Medical, LLC Anti-uroplakin ii antibodies systems and methods
US10429390B2 (en) 2012-12-18 2019-10-01 Biocare Medical, Llc Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer
ES2720483T3 (es) 2013-02-28 2019-07-22 Biocare Medical Llc Sistemas y procedimientos de anticuerpos anti p40
US9816997B2 (en) 2013-10-03 2017-11-14 Biocare Medical, Llc Anti-SOX10 antibody systems and methods
MX2019008970A (es) * 2017-01-30 2019-12-19 Abay Sa Ensayos de socio de unión específico de plasmón basados en solución y nanoestructuras metálicas.
WO2018226891A1 (en) * 2017-06-06 2018-12-13 Northwestern University Trans-interfacial magnetic separation
US20230193246A1 (en) * 2020-03-05 2023-06-22 BioLegend, Inc. Methods and compositions for detecting targets
EP4154002A4 (en) * 2020-05-21 2024-05-01 The Chinese University Of Hong Kong Thermodynamically stabilized antibodies for deep immunolabeling and tissue imaging
WO2022119937A1 (en) * 2020-12-03 2022-06-09 Ortho-Clinical Diagnostics, Inc. Lithium heparin as a blocking agent

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4511502A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
FR2556840B1 (fr) 1983-12-16 1987-12-24 Immunotech Sa Procede de dosage in vitro des immunoglobulines specifiques d'un ou plusieurs allergenes et reactifs et moyens pour la mise en oeuvre de ce procede
US4847081A (en) * 1984-07-18 1989-07-11 W. R. Grace & Co.-Conn. Synthetic bovine parainfluenza viral proteins
US4658022A (en) * 1985-08-08 1987-04-14 Molecular Diagnostics, Inc. Binding of antibody reagents to denatured protein analytes
US4737453A (en) 1984-12-12 1988-04-12 Immunomedics, Inc. Sandwich immunoassay utilizing a separation specific binding substance
JPH073424B2 (ja) * 1986-03-31 1995-01-18 日東電工株式会社 免疫学的診断試薬
US4678553A (en) * 1986-07-11 1987-07-07 Ionics, Incorporated Renaturing reversibly denatured polypeptides and proteins by electrodialysis of solutions thereof in denaturants
DE68907996T2 (de) * 1988-05-11 1994-01-05 Abbott Lab Verfahren zur Erhöhung der Spezifizität in kompetitiven Immuntests.
US5656426A (en) 1988-08-01 1997-08-12 Chiron Diagnostics Corporation Functionaized hydrophilic acridinium esters
JPH0436185A (ja) * 1990-03-28 1992-02-06 Kyowa Hakko Kogyo Co Ltd 融合抗原ポリペプチド
JP3269642B2 (ja) * 1990-06-25 2002-03-25 財団法人阪大微生物病研究会 非Ａ非Ｂ型肝炎ウイルス遺伝子ｃＤＮＡおよび抗原ポリペプチド
US5284932A (en) * 1990-09-07 1994-02-08 The Cleveland Clinic Foundation Process for purifying and characterizing myotrophia, a novel peptide that regulates myocardial growth
EP0556331A4 (en) 1990-11-09 1994-10-12 Abbott Lab AMPLIFIED HETEROGENIC CHEMILUMINESCENCE IMMUNOASSAY.
ATE229543T1 (de) 1991-06-24 2002-12-15 Chiron Corp Polypeptide des hepatitis c-virus (hiv)
JPH06505803A (ja) 1992-01-06 1994-06-30 デイド、インターナショナル、インコーポレイテッド マルチテスト免疫化学的試薬及びその使用方法
JP3225468B2 (ja) * 1992-08-28 2001-11-05 ダイナボット株式会社 抗体測定用試薬
CN1105181A (zh) 1993-04-14 1995-07-12 国际莫莱斯技术公司 免疫测定法
KR100312534B1 (ko) * 1993-04-28 2002-05-13 성재갑 씨(c)형간염및비(b)형간염동시측정면역블롯검정키트및면역블롯검정법
AU6913394A (en) 1993-05-13 1994-12-12 United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nucleic acid tagged immunoassay
DE19502386A1 (de) * 1995-01-26 1996-08-01 Boehringer Mannheim Gmbh Stabilisierung von Peptiden und Polypeptiden in immunologischen Tests durch Zusatz von kleinen Hitzeschockproteinen
US5705330A (en) 1995-04-14 1998-01-06 Abbott Laboratories Chemiluminescent immunoassay for antibody detection
US5616460A (en) * 1995-06-07 1997-04-01 Abbott Laboratories Buffer composition for reagents for immunoassay
JPH09127114A (ja) * 1995-11-01 1997-05-16 Dainabotsuto Kk 免疫学的測定用安定化ＩｇＭ試薬
ES2251028T3 (es) 1996-05-24 2006-04-16 Chiron Corporation Proteina de fusion de epitopos multiples.
DE69840334D1 (de) * 1997-09-22 2009-01-22 Novartis Vaccines & Diagnostic Puffern zur stabilizierung von hcv antigenen

Also Published As

Publication number Publication date
AU9498098A (en) 1999-04-12
WO1999015901A1 (en) 1999-04-01
US6261764B1 (en) 2001-07-17
ATE417275T1 (de) 2008-12-15
JP2009180750A (ja) 2009-08-13
CA2303165A1 (en) 1999-04-01
US20010039009A1 (en) 2001-11-08
JP2001517799A (ja) 2001-10-09
JP4427182B2 (ja) 2010-03-03
ES2316171T3 (es) 2009-04-01
EP1021723B1 (en) 2008-12-10
US6537745B2 (en) 2003-03-25
EP1021723A1 (en) 2000-07-26
CA2303165C (en) 2006-07-11

Similar Documents

Publication Publication Date Title
DE69840334D1 (de) Puffern zur stabilizierung von hcv antigenen
ATE172743T1 (de) Nachweis von kollagenabbau -i(in vivo)
DK1476541T3 (da) Cytokin (zcytor17-ligand)
ATE317441T1 (de) Cathepsin-02-protease
CY1114164T1 (el) Μεθοδος ελεγχου της δραστικοτητας ανοσολογικα λειτουργικου μοριου
AU5055593A (en) Antibodies specific for HIV
ES2129487T3 (es) Peptidos sinteticos, anticuerpos dirigidos contra ellos y su utilizacion.
FI972390A0 (fi) Sytokiini nimeltä Lerk-7
DK1576112T3 (da) Cytokin-receptor zcytor17-multimerer
UY28641A1 (es) Anticuerpos
DK0733069T3 (da) Oprensede Primat CTLA-8-antigener og beslægtede reagenser
DE60019458D1 (de) Stabilisierendes verdünnungsmittel für polypeptide und antigene
PT698216E (pt) Metodos de tipificacao do virus da hepatite c e reagentes para utilizar nestes
DE59508474D1 (de) RHEUMAFAKTOR-ENTSTÖRUNG MIT ANTI-Fd-ANTIKÖRPERN
ATE162553T1 (de) Monoklonale antikörper gegen hepatitis-c-virus
EP1326895B8 (fr) Anticorps monoclonaux diriges contre des virus de l'hepatite b
DE60324003D1 (en) Hcv-test
EA200400392A1 (ru) Связывающий каспазу-8 белок, его получение и применение
DE59709495D1 (de) Antikörper und immunoassay zum Nachweis von MIA
FI943218A7 (fi) Kaseinomakropeptidin peptidit, mainittujen peptidien vasta-aineet ja k äytöt
RU2004106775A (ru) Антитело против интерферон-альфа/бета-связывающего белка i (ifnab-bpi)
ATE320266T1 (de) Induktion von antigen-spezifischen t-zellen durch interferon
ES2126598T3 (es) Anticuerpos monoclonales que se fijan sobre las proteinas ns5 supuestas del virus de la hepatitis c, y procedimientos de utilizacion de estos anticuerpos.
ATE307201T1 (de) Srcr domäne-enthaltendes protein
DE69130675D1 (de) Klonierung und expression eines rhoptry-assoziierten proteins aus p. falciparum

Legal Events

Date Code Title Description
8364 No opposition during term of opposition